https://www.onclive.com/view/dr-randall-on-long-term-responses-and-functional-benefits-with-pimicotinib-in-tgct2026-05-08T21:13:21.780Z2026-05-08T21:13:21.780Z https://www.onclive.com/view/post-t-dxd-sacituzumab-govitecan-plus-trastuzumab-yields-low-orr-in-her2-metastatic-breast-cancer2026-05-08T20:50:43.847Z2026-05-08T20:50:43.847Z https://www.onclive.com/view/dr-sznol-on-the-nuances-of-recommending-neoadjuvant-therapy-in-metastatic-melanoma2026-05-08T20:25:00Z2026-05-08T20:25:00Z https://www.onclive.com/view/biomarker-directed-therapies-move-the-gi-oncology-paradigm-beyond-a-one-size-fits-all-approach-with-michael-j-pishvaian-md-phd2026-05-08T20:11:42.197Z2026-05-08T20:11:42.197Z https://www.onclive.com/view/capivasertib-fulvestrant-yields-numerical-os-advantage-in-pik3ca-akt1-pten-altered-breast-cancer2026-05-08T20:08:48.445Z2026-05-08T20:08:48.445Z https://www.onclive.com/view/fda-approves-zenocutuzumab-for-nrg1-fusion-cholangiocarcinoma2026-05-08T18:55:35.027Z2026-05-08T18:55:35.027Z https://www.onclive.com/view/ut-md-anderson-shares-latest-research-breakthroughs2026-05-08T16:00:00Z2026-05-08T16:00:00Z https://www.onclive.com/view/giants-of-cancer-care-announces-the-14th-annual-class-of-inductees2026-05-08T15:31:44.649Z2026-05-08T15:31:44.649Z https://www.onclive.com/view/onclive-weekly-news-quiz-5-8-2026-test-your-knowledge-on-key-breast-lung-and-pancreatic-cancer-updates2026-05-08T15:30:00Z2026-05-08T15:30:00Z https://www.onclive.com/view/onclive-polls-reveal-picks-for-top-lung-cancer-abstracts-at-asco-20262026-05-08T14:08:54.179Z2026-05-08T14:08:54.179Z https://www.onclive.com/view/poll-results-highlight-breast-cancer-abstracts-of-interest-at-asco-20262026-05-08T14:08:09.146Z2026-05-08T14:08:09.146Z https://www.onclive.com/view/dr-gruenbaum-on-where-alternative-options-to-btk-inhibitors-stand-in-mcl2026-05-08T13:00:00Z2026-05-08T13:00:00Z https://www.onclive.com/view/the-pynnacle-phase-2-trial-assessing-rezatapopt-a-selective-p53-reactivator-in-patients-with-advanced-or-metastatic-solid-tumors-harboring-a-tp53-y220c-mutation-interim-analysis-of-patients-with-ovarian-cancer2026-05-08T12:07:31.158Z2026-05-08T12:07:31.158Z https://www.onclive.com/view/cumulative-adc-toxicities-and-closing-reflections-managing-edema-fatigue-and-optimizing-long-term-tolerability2026-05-08T12:00:00Z2026-05-08T12:00:00Z https://www.onclive.com/view/first-line-danvatirsen-plus-pembrolizumab-fails-to-improve-response-rates-in-metastatic-hnscc2026-05-08T12:00:00Z2026-05-08T12:00:00Z https://www.onclive.com/view/characterization-and-management-of-sevabertinib-induced-diarrhea-in-the-soho-1-study2026-05-08T12:00:00Z2026-05-08T12:00:00Z https://www.onclive.com/view/dr-sznol-on-optimal-treatment-sequencing-in-melanoma2026-05-07T23:00:00Z2026-05-07T23:00:00Z https://www.onclive.com/view/mentorship-is-key-to-advance-the-next-generation-of-oncology-researchers2026-05-07T21:24:45.839Z2026-05-07T21:24:45.839Z https://www.onclive.com/view/dr-mauro-on-the-significance-of-alternative-tki-formulations-in-cml2026-05-07T21:23:39.862Z2026-05-07T21:23:39.862Z https://www.onclive.com/view/women-with-bladder-cancer-face-diagnostic-delays-as-symptoms-mimic-utis-experts-warn2026-05-07T18:30:00Z2026-05-07T18:30:00Z https://www.onclive.com/view/dr-olawaiye-on-the-fda-approval-of-relacorilant-plus-nab-paclitaxel-in-proc2026-05-07T16:58:44.897Z2026-05-07T16:58:44.897Z https://www.onclive.com/view/daraxonrasib-monotherapy-elicits-meaningful-responses-in-previously-treated-ras-mutated-pancreatic-cancer2026-05-07T16:36:53.190Z2026-05-07T16:36:53.190Z https://www.onclive.com/view/sylvester-comprehensive-cancer-center-identifies-a-screening-gap-to-prevent-a-type-of-leukemia-in-the-u-s-2026-05-07T15:52:08.489Z2026-05-07T15:52:08.489Z https://www.onclive.com/view/fda-completes-type-a-meeting-following-crl-for-tabelecleucel-in-ebv-r-r-post-transplant-lymphoproliferative-disease2026-05-07T15:25:00Z2026-05-07T15:25:00Z https://www.onclive.com/view/asco-2026-tnbc-deep-dive-breast-cancer-experts-preview-practice-informing-studies2026-05-07T15:21:15.717Z2026-05-07T15:21:15.717Z https://www.onclive.com/view/track-the-lung-cancer-abstracts-that-are-gaining-attention-at-asco-20262026-05-07T13:00:00Z2026-05-07T13:00:00Z https://www.onclive.com/view/herizon-gea-01-study-design-geographic-distribution-and-pd-l1-testing-considerations2026-05-07T12:05:00Z2026-05-07T12:05:00Z https://www.onclive.com/view/egfr-targeted-therapy-sequencing-after-resistance-in-nsclc2026-05-07T12:05:00Z2026-05-07T12:05:00Z https://www.onclive.com/view/reigniting-your-curiosity-during-fellowship2026-05-07T12:00:00Z2026-05-07T12:00:00Z https://www.onclive.com/view/evaluating-observational-and-propensity-matched-studies-in-metastatic-castration-sensitive-prostate-cancer-mcspc-2026-05-07T12:00:00Z2026-05-07T12:00:00Z https://www.onclive.com/view/co-occurring-mutations-in-nsclc-influence-on-prognosis-and-immunotherapy-response2026-05-07T12:00:00Z2026-05-07T12:00:00Z https://www.onclive.com/view/approaching-first-line-treatment-in-pd-l1-cps-1-her2-positive-gea2026-05-07T12:00:00Z2026-05-07T12:00:00Z https://www.onclive.com/view/integrating-evidence-and-identifying-future-research-needs-in-metastatic-castration-sensitive-prostate-cancer-mcspc-2026-05-07T12:00:00Z2026-05-07T12:00:00Z https://www.onclive.com/view/manuever-trial-underscores-potential-paradigm-shift-toward-targeted-approaches-in-tgct2026-05-06T23:13:01.078Z2026-05-06T23:13:01.078Z https://www.onclive.com/view/dr-mcgregor-on-the-dad-io-trial-of-sacituzumab-govitecan-and-ev-in-metastatic-urothelial-carcinoma2026-05-06T19:22:31.509Z2026-05-06T19:22:31.509Z https://www.onclive.com/view/neoadjuvant-t-dxd-followed-by-thp-improves-rcb-in-her2-breast-cancer2026-05-06T19:16:58.298Z2026-05-06T19:16:58.298Z https://www.onclive.com/view/dr-lee-on-research-collaborations-studying-pd-l1-as-a-biomarker-in-nsclc2026-05-06T19:00:00Z2026-05-06T19:00:00Z https://www.onclive.com/view/dr-chari-on-frontline-combinations-and-transplant-approaches-in-multiple-myeloma2026-05-06T18:58:54.072Z2026-05-06T18:58:54.072Z https://www.onclive.com/view/fda-accepts-snda-for-taletrectinib-in-ros1-nsclc2026-05-06T17:36:48.389Z2026-05-06T17:36:48.389Z https://www.onclive.com/view/cases-and-conversations-next-generation-pathology-advances-and-considerations-for-precision-care-in-non-small-cell-lung-cancer2026-05-06T16:55:15.505Z2026-05-06T16:55:15.505Z https://www.onclive.com/view/dr-herrera-on-the-significance-of-the-fda-approval-of-nivolumab-plus-avd-for-classical-hodgkin-lymphoma2026-05-06T16:36:20.819Z2026-05-06T16:36:20.819Z https://www.onclive.com/view/dr-sznol-on-biomarkers-of-response-in-metastatic-melanoma2026-05-06T16:15:00Z2026-05-06T16:15:00Z https://www.onclive.com/view/transformational-utah-investment-in-artificial-intelligence-and-computing-to-advance-health-and-discovery2026-05-06T16:00:00Z2026-05-06T16:00:00Z https://www.onclive.com/view/asco-2026-breast-cancer-preview-read-up-on-the-insights-to-know-before-you-go2026-05-06T14:07:07.191Z2026-05-06T14:07:07.191Z https://www.onclive.com/view/consensus-viewpoints-offer-guidance-in-rapidly-evolving-multiple-myeloma-management2026-05-06T13:03:02.159Z2026-05-06T13:03:02.159Z https://www.onclive.com/view/comparing-approved-checkpoint-inhibitor-regimens-and-optimal-treatment-duration2026-05-06T12:05:00Z2026-05-06T12:05:00Z https://www.onclive.com/view/disease-assessment-and-mutational-testing-in-progressive-cll2026-05-06T12:04:00Z2026-05-06T12:04:00Z https://www.onclive.com/view/clinical-scenario-presentation-and-treatment-approach-for-progressive-disease2026-05-06T12:01:00Z2026-05-06T12:01:00Z https://www.onclive.com/view/four-year-follow-up-outcomes-in-dmmr-endometrial-cancer-presented-at-sgo-20262026-05-06T12:00:00Z2026-05-06T12:00:00Z https://www.onclive.com/view/dr-pant-on-the-mechanism-of-action-of-daraxonrasib-in-pdac2026-05-06T12:00:00Z2026-05-06T12:00:00Z https://www.onclive.com/view/simlukafusp-alfa-regimens-show-manageable-safety-and-activity-but-do-not-outperform-soc-in-metastatic-rcc2026-05-05T20:42:07.704Z2026-05-05T20:42:07.704Z https://www.onclive.com/view/dr-cohen-on-frontline-chemotherapy-selection-in-metastatic-pancreatic-cancer2026-05-05T20:01:49.496Z2026-05-05T20:01:49.496Z https://www.onclive.com/view/dr-pant-on-managing-toxicities-with-daraxonrasib-in-pdac2026-05-05T19:24:50.355Z2026-05-05T19:24:50.355Z https://www.onclive.com/view/hs-10504-shows-promising-activity-in-egfr-c797s-mutant-nsclc-after-tki-resistance2026-05-05T18:00:00Z2026-05-05T18:00:00Z https://www.onclive.com/view/breast-cancer-experts-preview-abstracts-to-watch-at-the-2026-esmo-breast-cancer-congress2026-05-05T16:17:51.212Z2026-05-05T16:17:51.212Z https://www.onclive.com/view/the-type-of-fat-not-the-amount-fuels-pancreatic-cancer2026-05-05T16:00:00Z2026-05-05T16:00:00Z https://www.onclive.com/view/iopofosine-i-131-follow-up-data-show-strong-efficacy-in-waldenstr-m-macroglobulinemia2026-05-05T14:24:03.485Z2026-05-05T14:24:03.485Z https://www.onclive.com/view/dr-mcgregor-on-key-end-points-of-the-strike-trial-of-tivozanib-plus-pembrolizumab-in-rcc2026-05-05T13:58:55.937Z2026-05-05T13:58:55.937Z https://www.onclive.com/view/dr-kuykendall-on-the-evolving-jak-inhibitor-and-transplant-considerations-in-myelofibrosis2026-05-05T13:00:00Z2026-05-05T13:00:00Z https://www.onclive.com/view/egfr-mutated-nsclc-molecular-reassessment-at-disease-progression2026-05-05T12:05:00Z2026-05-05T12:05:00Z https://www.onclive.com/view/coordinating-care-in-multiple-myeloma-across-practice-settings2026-05-05T12:05:00Z2026-05-05T12:05:00Z https://www.onclive.com/view/new-endometrial-targets-beyond-her22026-05-05T12:05:00Z2026-05-05T12:05:00Z https://www.onclive.com/view/new-understandings-of-treatments-end-points-and-disease-biology-expand-mcl-horizons2026-05-05T12:00:21.975Z2026-05-05T12:00:21.975Z https://www.onclive.com/view/white-blood-cell-count-as-independent-thrombotic-risk-factor-and-symptom-burden-assessment2026-05-05T12:00:00Z2026-05-05T12:00:00Z https://www.onclive.com/view/addressing-access-barriers-in-relapsed-and-refractory-multiple-myeloma2026-05-05T12:00:00Z2026-05-05T12:00:00Z https://www.onclive.com/view/egfr-mutated-nsclc-communicating-toxicity-and-treatment-burden2026-05-05T12:00:00Z2026-05-05T12:00:00Z https://www.onclive.com/view/managing-progression-after-immunotherapy-in-endometrial-cancer2026-05-05T12:00:00Z2026-05-05T12:00:00Z https://www.onclive.com/view/drs-lee-and-saxena-on-incorporating-pd-l1-expression-as-a-biomarker-in-egfr-mutated-nsclc-management2026-05-04T23:35:00Z2026-05-04T23:35:00Z https://www.onclive.com/view/metastatic-bladder-cancer-2026-update2026-05-04T23:20:00Z2026-05-04T23:20:00Z https://www.onclive.com/view/april-roundup-of-fda-approvals-in-oncology-2-decisions-to-know2026-05-04T22:29:07.307Z2026-05-04T22:29:07.307Z https://www.onclive.com/view/dr-sznol-on-overcoming-primary-and-acquired-resistance-in-metastatic-melanoma2026-05-04T22:15:00Z2026-05-04T22:15:00Z https://www.onclive.com/view/dr-gross-on-raising-awareness-for-skin-cancer-in-light-of-melanoma-monday2026-05-04T22:10:00Z2026-05-04T22:10:00Z https://www.onclive.com/view/dr-mcgregor-on-the-strike-trial-of-tivozanib-plus-pembrolizumab-in-rcc2026-05-04T17:05:09.235Z2026-05-04T17:05:09.235Z https://www.onclive.com/view/gedatolisib-based-combinations-beat-alpelisib-based-soc-in-pik3ca-mutant-hr-breast-cancer2026-05-04T16:25:06.188Z2026-05-04T16:25:06.188Z https://www.onclive.com/view/roswell-park-experts-highlight-untapped-potential-of-cdk-inhibitor-cancer-therapy2026-05-04T16:00:00Z2026-05-04T16:00:00Z https://www.onclive.com/view/pelareorep-combination-demonstrates-durable-responses-in-second-line-ras-mutant-mss-crc2026-05-04T15:06:53.251Z2026-05-04T15:06:53.251Z https://www.onclive.com/view/dr-pant-on-landmark-efficacy-data-with-daraxonrasib-in-previously-treated-metastatic-pdac2026-05-04T14:36:36.700Z2026-05-04T14:36:36.700Z https://www.onclive.com/view/fda-approves-companion-diagnostic-for-vepdegestrant-in-esr1-er-her2-negative-advanced-breast-cancer2026-05-04T14:31:05.652Z2026-05-04T14:31:05.652Z https://www.onclive.com/view/emerging-role-of-urinary-tumor-dna-utdna2026-05-04T12:05:00Z2026-05-04T12:05:00Z https://www.onclive.com/view/treatment-sequencing-and-regimen-selection-in-plgg2026-05-04T12:05:00Z2026-05-04T12:05:00Z https://www.onclive.com/view/renal-cell-carcinoma-translating-trial-data-to-real-world-practice2026-05-04T12:05:00Z2026-05-04T12:05:00Z https://www.onclive.com/view/final-perspectives-and-key-messages2026-05-04T12:00:00Z2026-05-04T12:00:00Z https://www.onclive.com/view/mri-interpretation-hemorrhage-and-multidisciplinary-monitoring-in-plgg2026-05-04T12:00:00Z2026-05-04T12:00:00Z https://www.onclive.com/view/duvelisib-yields-strong-efficacy-durable-responses-in-r-r-ptcl2026-05-04T12:00:00Z2026-05-04T12:00:00Z https://www.onclive.com/view/renal-cell-carcinoma-interpreting-cross-trial-comparisons2026-05-04T12:00:00Z2026-05-04T12:00:00Z https://www.onclive.com/view/ctdna-in-chemoradiotherapy-and-bladder-preservation2026-05-04T12:00:00Z2026-05-04T12:00:00Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-4-262026-05-04T00:57:00Z2026-05-04T00:57:00Z https://www.onclive.com/view/april-s-gi-monthly-rewind-key-regulatory-updates-you-may-have-missed2026-05-03T12:02:07.535Z2026-05-03T12:02:07.535Z https://www.onclive.com/view/fda-grants-rmat-designation-to-orca-q-for-high-risk-hematologic-malignancies2026-05-02T12:00:00Z2026-05-02T12:00:00Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-4-262026-05-02T10:00:00Z2026-05-02T10:00:00Z https://www.onclive.com/view/fda-clears-once-daily-ruxolitinib-tablets-for-myelofibrosis-polycythemia-vera-and-gvhd2026-05-01T22:23:02.195Z2026-05-01T22:23:02.195Z https://www.onclive.com/view/fda-green-lights-expanded-access-protocol-for-daraxonrasib-in-pretreated-metastatic-pdac2026-05-01T20:03:37.506Z2026-05-01T20:03:37.506Z https://www.onclive.com/view/show-me-the-data-from-mutation-to-action-kras-as-a-therapeutic-target-in-pdac2026-05-01T19:12:09.806Z2026-05-01T19:12:09.806Z https://www.onclive.com/view/nivolumab-plus-cabozantinib-displays-real-world-efficacy-in-first-line-advanced-rcc2026-05-01T18:00:00Z2026-05-01T18:00:00Z https://www.onclive.com/view/dr-danilov-on-how-to-approach-second-line-treatment-selection-for-cll2026-05-01T17:45:00Z2026-05-01T17:45:00Z https://www.onclive.com/view/fda-flashback-breast-cancer-decisions-and-news-from-april-20262026-05-01T17:30:38.326Z2026-05-01T17:30:38.326Z https://www.onclive.com/view/dr-sznol-on-frontline-standards-of-care-in-advanced-or-metastatic-melanoma2026-05-01T17:15:00Z2026-05-01T17:15:00Z https://www.onclive.com/view/fda-approves-vepdegestrant-for-er-her2-advanced-breast-cancer-with-an-esr1-mutation2026-05-01T16:37:30.253Z2026-05-01T16:37:30.253Z https://www.onclive.com/view/dana-farber-experts-offer-perspective-on-link-between-pesticide-exposure-and-early-onset-colorectal-cancer2026-05-01T16:00:00Z2026-05-01T16:00:00Z https://www.onclive.com/view/onclive-weekly-news-quiz-5-1-2026-are-you-caught-up-on-2-fda-odac-votes-in-prostate-and-breast-cancer-2026-05-01T14:48:39.404Z2026-05-01T14:48:39.404Z